Related Experiment Video
Updated: May 14, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Therapeutic challenges in advanced renal cell carcinoma
1Division of Hematology & Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, MASCO 4th Floor, Boston, MA 02215, USA; Tel.: +1 617 632 9250; ; dcho1@bidmc.harvard.edu.
Abstract:
The therapeutic landscape of advanced renal cell carcinoma has grown increasingly more complex with the recent approval of several molecularly targeted agents. While researchers focus on developing predictive algorithms and identifying novel therapeutic targets and agents, clinical practitioners continue to face many practical challenges when determining therapeutic strategies for individual patients. This review will discuss several of these challenges including patient selection strategies, sequential therapy, optimal dose and schedule of various drugs, and therapeutic options for patients with nonclear-cell renal cell carcinoma.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Treatment Resistent Cancers
Kidney Transplant III: Nursing Management
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Chronic Kidney Disease IV: Nursing Management
Tumor Immunotherapy

